What is Metrion Biosciences?
Metrion Biosciences operates at the intersection of advanced neuroscience and cardiac safety, providing high-quality preclinical drug discovery services. The company is widely recognized for its expertise in ion channel screening, high-throughput screening, and GLP hERG testing. By offering integrated drug discovery solutions, Metrion Biosciences empowers pharmaceutical research and development teams to overcome complex biological challenges. Their commitment to delivering reliable, high-fidelity data has established them as a preferred partner for organizations seeking to accelerate their pipeline development while ensuring rigorous safety standards. The company's unique value proposition lies in its ability to combine deep scientific knowledge with scalable, technology-driven research methodologies.
How much funding has Metrion Biosciences raised?
Metrion Biosciences has raised a total of $14.2M across 4 funding rounds:
Grant
$2.5M
Series B
$3.7M
Unspecified
$3.7M
Private Equity
$4.4M
Grant (2016): $2.5M, investors not publicly disclosed
Series B (2021): $3.7M led by Gresham House Asset Management
Unspecified (2021): $3.7M supported by Gresham House Ventures
Private Equity (2023): $4.4M featuring Maven Capital Partners UK and Gresham House Ventures
Key Investors in Metrion Biosciences
Maven Capital Partners UK
Maven Capital Partners UK LLP is a prominent private equity and venture capital firm that focuses on providing growth capital to high-potential businesses across various sectors.
Gresham House Asset Management
Gresham House is a specialist alternative asset manager that provides tailored investment solutions and strategic equity support to help companies achieve sustainable long-term financial returns.
Gresham House Ventures
Gresham House Ventures is a growth-focused investment arm that partners with ambitious management teams to scale innovative businesses through strategic capital and operational expertise.
What's next for Metrion Biosciences?
With the successful closure of this major strategic investment, Metrion Biosciences is well-positioned to accelerate its long-term growth strategy. The company is expected to leverage this capital to enhance its laboratory infrastructure and broaden its suite of preclinical services. By focusing on high-growth areas such as neuroscience and cardiac safety, Metrion aims to solidify its leadership in the CRO market. Future initiatives will likely prioritize the integration of new high-throughput technologies and the expansion of its international client base. As the pharmaceutical industry continues to demand more efficient and accurate preclinical data, Metrion Biosciences remains a key player in facilitating the transition of drug candidates from the laboratory to clinical trials.
See full Metrion Biosciences company page
